25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AMRX (Amneal) Stock Analysis
Buy, Hold or Sell?

Let's analyze Amneal together

I guess you are interested in Amneal Pharmaceuticals, Inc. Class A Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Amneal’s Financial Insights
  • 📈 Technical Analysis (TA) – Amneal’s Price Targets

I'm going to help you getting a better view of Amneal Pharmaceuticals, Inc. Class A Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Amneal Pharmaceuticals, Inc. Class A Common Stock

I send you an email if I find something interesting about Amneal Pharmaceuticals, Inc. Class A Common Stock.

1. Quick Overview

1.1. Quick analysis of Amneal (30 sec.)










1.2. What can you expect buying and holding a share of Amneal? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
29.4%

What is your share worth?

Current worth
$-0.18
Expected worth in 1 year
$-0.31
How sure are you?
44.1%

+ What do you gain per year?

Total Gains per Share
$-0.13
Return On Investment
-1.6%

For what price can you sell your share?

Current Price per Share
$8.37
Expected price per share
$7.02 - $9.1
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Amneal (5 min.)




Live pricePrice per Share (EOD)
$8.37
Intrinsic Value Per Share
$-14.75 - $-17.93
Total Value Per Share
$-14.93 - $-18.12

2.2. Growth of Amneal (5 min.)




Is Amneal growing?

Current yearPrevious yearGrowGrow %
How rich?-$59.3m$94.4m-$146m-282.8%

How much money is Amneal making?

Current yearPrevious yearGrowGrow %
Making money-$3.2m-$42.1m$38.9m1,192.9%
Net Profit Margin-0.4%-6.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Amneal (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Amneal?

Welcome investor! Amneal's management wants to use your money to grow the business. In return you get a share of Amneal.

First you should know what it really means to hold a share of Amneal. And how you can make/lose money.

Speculation

The Price per Share of Amneal is $8.37. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Amneal.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Amneal, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.18. Based on the TTM, the Book Value Change Per Share is $-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Amneal.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.040.4%-0.01-0.1%-0.13-1.6%-0.08-1.0%-0.05-0.6%-0.04-0.4%
Usd Book Value Change Per Share0.172.0%-0.03-0.4%-0.14-1.7%-0.12-1.5%-0.07-0.9%-0.01-0.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.070.9%
Usd Total Gains Per Share0.172.0%-0.03-0.4%-0.14-1.7%-0.12-1.5%-0.07-0.9%0.070.8%
Usd Price Per Share8.38-7.74-4.86-4.92-4.92-8.28-
Price to Earnings Ratio55.65--1,014.69-11.13--343.90--225.63--135.95-
Price-to-Total Gains Ratio50.46-21.92-34.88-17.74--22.81--12.54-
Price to Book Ratio-45.71--160.95--1.77--50.97--28.92--19.50-
Price-to-Total Gains Ratio50.46-21.92-34.88-17.74--22.81--12.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.37
Number of shares119
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.03-0.07
Usd Total Gains Per Share-0.03-0.07
Gains per Quarter (119 shares)-3.88-8.75
Gains per Year (119 shares)-15.51-34.99
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-16-260-35-45
20-31-420-70-80
30-47-580-105-115
40-62-740-140-150
50-78-900-175-185
60-93-1060-210-220
70-109-1220-245-255
80-124-1380-280-290
90-140-1540-315-325
100-155-1700-350-360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%11.023.00.032.4%11.023.00.032.4%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%8.012.00.040.0%12.020.02.035.3%12.020.02.035.3%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%10.00.024.029.4%10.00.024.029.4%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%8.012.00.040.0%15.019.00.044.1%15.019.00.044.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Amneal Pharmaceuticals, Inc. Class A Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.166-0.033+120%-0.143+186%-0.124+174%-0.074+144%-0.005+103%
Book Value Per Share---0.183-0.163-11%0.301-161%0.201-191%0.596-131%0.702-126%
Current Ratio--1.4041.381+2%1.756-20%1.632-14%1.906-26%1.871-25%
Debt To Asset Ratio--1.0181.015+0%0.974+4%0.984+3%0.953+7%0.974+4%
Debt To Equity Ratio--3.3690.842+300%49.040-93%22.621-85%17.800-81%5081209.416-100%
Dividend Per Share----0%-0%0.000-100%0.000-100%0.074-100%
Enterprise Value---650657820.000-981654267.500+51%-1877244750.000+189%-1929458705.833+197%-1867249413.500+187%-475575231.471-27%
Eps--0.038-0.011+129%-0.135+457%-0.084+324%-0.053+241%-0.037+199%
Ev To Ebitda Ratio---1.052-1.769+68%-3.439+227%-2.943+180%-3.661+248%-0.818-22%
Ev To Sales Ratio---0.234-0.347+48%-0.757+224%-0.799+241%-0.827+254%0.094-350%
Free Cash Flow Per Share---0.0340.186-118%0.099-134%0.094-136%0.147-123%0.107-131%
Free Cash Flow To Equity Per Share---0.1550.006-2750%-0.079-49%-0.041-73%-0.019-87%0.066-333%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.071-7%
Intrinsic Value_10Y_max---17.934----------
Intrinsic Value_10Y_min---14.748----------
Intrinsic Value_1Y_max--0.060----------
Intrinsic Value_1Y_min--0.060----------
Intrinsic Value_3Y_max---1.234----------
Intrinsic Value_3Y_min---1.150----------
Intrinsic Value_5Y_max---4.236----------
Intrinsic Value_5Y_min---3.810----------
Market Cap2623325400.000-3%2714793180.0002457527732.500+10%1524004750.000+78%1551272794.167+75%1547574236.500+75%2597920121.471+4%
Net Profit Margin--0.018-0.004+124%-0.066+476%-0.044+351%-0.028+262%-0.023+232%
Operating Margin--0.1360.115+18%0.129+6%0.076+78%0.076+78%0.077+75%
Operating Ratio--0.8560.872-2%0.871-2%0.884-3%0.905-5%0.895-4%
Pb Ratio-45.658+0%-45.712-160.951+252%-1.769-96%-50.974+12%-28.925-37%-19.499-57%
Pe Ratio55.5870%55.654-1014.693+1923%11.133+400%-343.903+718%-225.631+505%-135.951+344%
Price Per Share8.3700%8.3807.743+8%4.863+72%4.917+70%4.918+70%8.277+1%
Price To Free Cash Flow Ratio-62.112+0%-62.186-8.079-87%-5.122-92%-4.551-93%-1.084-98%5.680-1195%
Price To Total Gains Ratio50.3950%50.45521.923+130%34.877+45%17.738+184%-22.810+145%-12.536+125%
Quick Ratio--0.7990.774+3%0.956-16%0.889-10%1.107-28%1.122-29%
Return On Assets--0.004-0.001+125%-0.012+439%-0.007+301%-0.005+228%0.000+2479%
Return On Equity--0.0120.003+300%-1.230+10353%-0.455+3888%-0.276+2398%151573.338-100%
Total Gains Per Share--0.166-0.033+120%-0.143+186%-0.124+174%-0.074+144%0.069+141%
Usd Book Value---59389000.000-51662000.000-13%94414500.000-163%62948666.667-194%186702700.000-132%220055264.706-127%
Usd Book Value Change Per Share--0.166-0.033+120%-0.143+186%-0.124+174%-0.074+144%-0.005+103%
Usd Book Value Per Share---0.183-0.163-11%0.301-161%0.201-191%0.596-131%0.702-126%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%0.074-100%
Usd Enterprise Value---650657820.000-981654267.500+51%-1877244750.000+189%-1929458705.833+197%-1867249413.500+187%-475575231.471-27%
Usd Eps--0.038-0.011+129%-0.135+457%-0.084+324%-0.053+241%-0.037+199%
Usd Free Cash Flow---10914000.00058341250.000-119%31060750.000-135%29368833.333-137%46073750.000-124%33664205.882-132%
Usd Free Cash Flow Per Share---0.0340.186-118%0.099-134%0.094-136%0.147-123%0.107-131%
Usd Free Cash Flow To Equity Per Share---0.1550.006-2750%-0.079-49%-0.041-73%-0.019-87%0.066-333%
Usd Market Cap2623325400.000-3%2714793180.0002457527732.500+10%1524004750.000+78%1551272794.167+75%1547574236.500+75%2597920121.471+4%
Usd Price Per Share8.3700%8.3807.743+8%4.863+72%4.917+70%4.918+70%8.277+1%
Usd Profit--12195000.000-3262000.000+127%-42173250.000+446%-26740916.667+319%-17036750.000+240%-15745794.118+229%
Usd Revenue--695420000.000707546500.000-2%623814500.000+11%633137916.667+10%584147350.000+19%494208058.824+41%
Usd Total Gains Per Share--0.166-0.033+120%-0.143+186%-0.124+174%-0.074+144%0.069+141%
 EOD+2 -6MRQTTM+23 -14YOY+24 -133Y+23 -165Y+24 -1510Y+19 -21

3.3 Fundamental Score

Let's check the fundamental score of Amneal Pharmaceuticals, Inc. Class A Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1555.587
Price to Book Ratio (EOD)Between0-1-45.658
Net Profit Margin (MRQ)Greater than00.018
Operating Margin (MRQ)Greater than00.136
Quick Ratio (MRQ)Greater than10.799
Current Ratio (MRQ)Greater than11.404
Debt to Asset Ratio (MRQ)Less than11.018
Debt to Equity Ratio (MRQ)Less than13.369
Return on Equity (MRQ)Greater than0.150.012
Return on Assets (MRQ)Greater than0.050.004
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Amneal Pharmaceuticals, Inc. Class A Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.611
Ma 20Greater thanMa 507.885
Ma 50Greater thanMa 1007.616
Ma 100Greater thanMa 2007.874
OpenGreater thanClose8.210
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Amneal Pharmaceuticals, Inc. Class A Common Stock

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Fundamental data was last updated by Penke on 2025-06-21 02:20:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Amneal earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 1.8% means that $0.02 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 1.8%. The company is making a profit. +1
  • The TTM is -0.4%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM-0.4%+2.2%
TTM-0.4%YOY-6.6%+6.2%
TTM-0.4%5Y-2.8%+2.4%
5Y-2.8%10Y-2.3%-0.5%
4.3.1.2. Return on Assets

Shows how efficient Amneal is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.4% Return on Assets means that Amneal generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 0.4%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -0.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.4%TTM-0.1%+0.5%
TTM-0.1%YOY-1.2%+1.1%
TTM-0.1%5Y-0.5%+0.4%
5Y-0.5%10Y0.0%-0.5%
4.3.1.3. Return on Equity

Shows how efficient Amneal is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.2% Return on Equity means Amneal generated $0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 1.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.2%TTM0.3%+0.9%
TTM0.3%YOY-123.0%+123.3%
TTM0.3%5Y-27.6%+27.9%
5Y-27.6%10Y15,157,333.8%-15,157,361.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Amneal Pharmaceuticals, Inc. Class A Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Amneal is operating .

  • Measures how much profit Amneal makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 13.6% means the company generated $0.14  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 13.6%. The company is operating less efficient.
  • The TTM is 11.5%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ13.6%TTM11.5%+2.0%
TTM11.5%YOY12.9%-1.3%
TTM11.5%5Y7.6%+3.9%
5Y7.6%10Y7.7%-0.1%
4.3.2.2. Operating Ratio

Measures how efficient Amneal is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.86 means that the operating costs are $0.86 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 0.856. The company is less efficient in keeping operating costs low.
  • The TTM is 0.872. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.856TTM0.872-0.016
TTM0.872YOY0.871+0.001
TTM0.8725Y0.905-0.034
5Y0.90510Y0.895+0.011
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Amneal Pharmaceuticals, Inc. Class A Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Amneal is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.40 means the company has $1.40 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 1.404. The company is just able to pay all its short-term debts.
  • The TTM is 1.381. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.404TTM1.381+0.023
TTM1.381YOY1.756-0.375
TTM1.3815Y1.906-0.525
5Y1.90610Y1.871+0.036
4.4.3.2. Quick Ratio

Measures if Amneal is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.80 means the company can pay off $0.80 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 0.799. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.774. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.799TTM0.774+0.025
TTM0.774YOY0.956-0.182
TTM0.7745Y1.107-0.333
5Y1.10710Y1.122-0.014
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Amneal Pharmaceuticals, Inc. Class A Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Amneal assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Amneal to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 1.02 means that Amneal assets are financed with 101.8% credit (debt) and the remaining percentage (100% - 101.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 1.018. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.015. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.018TTM1.015+0.003
TTM1.015YOY0.974+0.041
TTM1.0155Y0.953+0.062
5Y0.95310Y0.974-0.021
4.5.4.2. Debt to Equity Ratio

Measures if Amneal is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 336.9% means that company has $3.37 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The MRQ is 3.369. The company is unable to pay all its debts with equity. -1
  • The TTM is 0.842. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ3.369TTM0.842+2.527
TTM0.842YOY49.040-48.198
TTM0.8425Y17.800-16.958
5Y17.80010Y5,081,209.416-5,081,191.616
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Amneal generates.

  • Above 15 is considered overpriced but always compare Amneal to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 55.65 means the investor is paying $55.65 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The EOD is 55.587. Based on the earnings, the company is expensive. -2
  • The MRQ is 55.654. Based on the earnings, the company is expensive. -2
  • The TTM is -1,014.693. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD55.587MRQ55.654-0.066
MRQ55.654TTM-1,014.693+1,070.346
TTM-1,014.693YOY11.133-1,025.826
TTM-1,014.6935Y-225.631-789.062
5Y-225.63110Y-135.951-89.680
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The EOD is -62.112. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -62.186. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.079. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-62.112MRQ-62.186+0.074
MRQ-62.186TTM-8.079-54.107
TTM-8.079YOY-5.122-2.957
TTM-8.0795Y-1.084-6.995
5Y-1.08410Y5.680-6.764
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Amneal is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of -45.71 means the investor is paying $-45.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Amneal Pharmaceuticals, Inc. Class A Common Stock:

  • The EOD is -45.658. Based on the equity, the company is expensive. -2
  • The MRQ is -45.712. Based on the equity, the company is expensive. -2
  • The TTM is -160.951. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-45.658MRQ-45.712+0.055
MRQ-45.712TTM-160.951+115.239
TTM-160.951YOY-1.769-159.183
TTM-160.9515Y-28.925-132.027
5Y-28.92510Y-19.499-9.426
4.6.2. Total Gains per Share

2.4. Latest News of Amneal Pharmaceuticals, Inc. Class A Common Stock

Does Amneal Pharmaceuticals, Inc. Class A Common Stock still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Amneal Pharmaceuticals, Inc. Class A Common Stock to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-24
22:55
Amneal Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for AMRXRead
2025-06-12
14:42
Amneal Pharma Gets FDA Approval For Prednisolone Acetate Ophthalmic SuspensionRead
2025-06-06
19:40
Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and AmRead
2025-06-06
17:20
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics spaceRead
2025-06-04
20:07
Amneal recalls oral antibiotic due to bacterial contaminationRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Amneal Pharmaceuticals, Inc. Class A Common Stock.

4.8.1. Institutions holding Amneal Pharmaceuticals, Inc. Class A Common Stock

Institutions are holding 44.242% of the shares of Amneal Pharmaceuticals, Inc. Class A Common Stock.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Vanguard Group Inc5.02930.0024157627279207586.2037
2025-03-31BlackRock Inc4.01630.002212587778-232-0.0018
2025-03-31TPG GP A, LLC3.93362.03751232876700
2025-03-31Rubric Capital Management LP3.42541.612310735977141990.1324
2025-03-31Citadel Advisors Llc2.39040.01197492029-1488939-16.5788
2025-03-31Dimensional Fund Advisors, Inc.1.62820.010651031561114542.2328
2025-03-31Geode Capital Management, LLC1.22050.00253825411122040.32
2025-03-31Nantahala Capital Management, LLC1.21521.268238085611430323.9021
2025-03-31Neuberger Berman Group LLC1.19170.02633735083-27664-0.7352
2025-03-31State Street Corp1.17740.00133690354-7792-0.2107
2025-03-31BlackBarn Capital Partners LP0.91941.53592881654316541.1107
2024-12-31Nuveen Asset Management, LLC0.87290.00612735743-184836-6.3287
2025-03-31Acadian Asset Management LLC0.8290.061525982942332367877.0704
2025-03-31Nuveen, LLC0.74550.0059233662823366280
2025-03-31Amvescap Plc.0.72510.0036227271336546719.162
2025-03-31Millennium Management LLC0.6660.0093208739876284257.5923
2025-03-31Arrowstreet Capital Limited Partnership0.57220.0122179345325239516.378
2025-03-31Charles Schwab Investment Management Inc0.5640.0028176759422766014.7838
2025-03-31Qube Research & Technologies0.56350.0172176596546795936.0521
2025-03-31Northern Trust Corp0.54520.00211708627-68656-3.863
Total 32.23086.6318101017912+6200500+6.1%

4.9.2. Funds holding Amneal Pharmaceuticals, Inc. Class A Common Stock

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv1.57750.0022494420200
2025-05-31iShares Russell 2000 ETF1.28070.0477401408700
2025-04-30Vanguard Small Cap Index1.24060.02123888127263450.6822
2025-04-30Vanguard Small Cap Value Index Inv0.80220.0371251431379840.3186
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.73810.0174231335634080.1475
2025-03-31Fidelity Small Cap Index0.5040.05481579609101980.6498
2025-03-31Hennessy Cornerstone Growth Investor0.47842.5921499400-171200-10.2478
2025-05-31iShares Russell 2000 Growth ETF0.36770.0764115258300
2025-03-31Columbia Small Cap Value II0.35781.15991121364-8400-0.7435
2025-04-30Columbia Small Cap Value II Inst0.35781.1055112136400
2025-04-30Nuveen Quant Small Cap Equity R60.32490.25341018450-25330-2.4268
2025-04-30DFA US Small Cap I0.32060.0519100496900
2025-04-30Neuberger Berman Intrinsic Value I0.31370.7586983293-50584-4.8927
2025-05-30Dimensional US Small Cap ETF0.29510.069392487300
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.29010.016290926261000.6754
2025-04-30DFA US Micro Cap I0.27170.108385147100
2025-04-30Fidelity Extended Market Index0.26820.0179840708200342.4412
2025-04-30CREF Stock R30.26480.00548299269396212.7672
2025-05-30Invesco Pharmaceuticals ETF0.26232.5737822233-2806-0.3401
2025-04-30Vanguard Russell 2000 ETF0.2540.0516795995491166.5762
Total 10.57029.020533129585-41173-0.1%

5.3. Insider Transactions

Insiders are holding 46.753% of the shares of Amneal Pharmaceuticals, Inc. Class A Common Stock.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-03-14Tushar Bhikhubhai PatelSELL50000008.35
2025-03-03Gautam PatelSELL800008.9
2025-02-03Gautam PatelSELL800008.14
2025-01-08Gautam PatelSELL625908.01
2025-01-02Gautam PatelSELL174108.01
2024-11-15Jason B DalySELL436578.61
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Total Stockholder Equity -63,7246,259-57,465-35,967-93,432-15,835-109,2671,125,7021,016,435



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets3,365,249
Total Liabilities3,424,638
Total Stockholder Equity1,016,435
 As reported
Total Liabilities 3,424,638
Total Stockholder Equity+ 1,016,435
Total Assets = 3,365,249

Assets

Total Assets3,365,249
Total Current Assets1,510,450
Long-term Assets1,854,799
Total Current Assets
Cash And Cash Equivalents 59,187
Net Receivables 800,294
Inventory 601,433
Other Current Assets 49,536
Total Current Assets  (as reported)1,510,450
Total Current Assets  (calculated)1,510,450
+/-0
Long-term Assets
Property Plant Equipment 522,748
Goodwill 597,497
Intangible Assets 689,136
Long-term Assets Other 45,418
Long-term Assets  (as reported)1,854,799
Long-term Assets  (calculated)1,854,799
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,075,824
Long-term Liabilities2,348,814
Total Stockholder Equity1,016,435
Total Current Liabilities
Short-term Debt 337,544
Short Long Term Debt 321,790
Accounts payable 192,532
Other Current Liabilities 545,748
Total Current Liabilities  (as reported)1,075,824
Total Current Liabilities  (calculated)1,397,614
+/- 321,790
Long-term Liabilities
Long term Debt 2,153,979
Capital Lease Obligations 103,732
Long-term Liabilities Other 80,086
Long-term Liabilities  (as reported)2,348,814
Long-term Liabilities  (calculated)2,337,797
+/- 11,017
Total Stockholder Equity
Retained Earnings -594,867
Other Stockholders Equity 1,562,241
Total Stockholder Equity (as reported)1,016,435
Total Stockholder Equity (calculated)967,374
+/- 49,061
Other
Capital Stock3,134
Cash and Short Term Investments 59,187
Common Stock Shares Outstanding 323,961
Liabilities and Stockholders Equity 3,365,249
Net Debt 2,520,314
Net Invested Capital 2,344,102
Net Working Capital 434,626
Property Plant and Equipment Gross 522,748
Short Long Term Debt Total 2,579,501



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
1,218,817
1,218,817
1,218,817
1,239,611
1,341,889
1,358,788
4,544,588
4,582,048
4,352,736
4,384,586
4,262,139
3,703,943
3,665,890
4,390,800
4,056,756
4,037,536
4,006,033
3,960,070
4,023,053
3,974,409
3,939,664
3,888,968
4,041,405
3,874,039
3,799,341
3,626,605
3,700,886
3,687,079
3,472,569
3,456,397
3,509,922
3,460,978
3,501,445
3,365,249
3,365,2493,501,4453,460,9783,509,9223,456,3973,472,5693,687,0793,700,8863,626,6053,799,3413,874,0394,041,4053,888,9683,939,6643,974,4094,023,0533,960,0704,006,0334,037,5364,056,7564,390,8003,665,8903,703,9434,262,1394,384,5864,352,7364,582,0484,544,5881,358,7881,341,8891,239,6111,218,8171,218,8171,218,817
   > Total Current Assets 
726,114
31,721
0
693,513
771,933
48,200
1,347,894
1,431,301
1,286,644
1,267,968
1,185,847
1,205,831
1,210,210
1,773,700
1,480,874
1,543,719
1,551,539
1,559,661
1,563,475
1,570,337
1,520,108
1,389,678
1,553,601
1,419,832
1,411,818
1,307,325
1,421,789
1,456,075
1,377,863
1,380,044
1,485,480
1,513,294
1,587,806
1,510,450
1,510,4501,587,8061,513,2941,485,4801,380,0441,377,8631,456,0751,421,7891,307,3251,411,8181,419,8321,553,6011,389,6781,520,1081,570,3371,563,4751,559,6611,551,5391,543,7191,480,8741,773,7001,210,2101,205,8311,185,8471,267,9681,286,6441,431,3011,347,89448,200771,933693,513031,721726,114
       Cash And Cash Equivalents 
27,367
-31,721
0
19,348
74,166
48,200
61,521
165,192
213,394
63,946
54,893
212,738
151,197
405,238
266,143
281,278
341,378
452,097
278,306
302,655
247,790
210,477
91,979
87,335
25,976
144,674
109,284
86,929
91,542
46,520
43,769
74,006
110,552
59,187
59,187110,55274,00643,76946,52091,54286,929109,284144,67425,97687,33591,979210,477247,790302,655278,306452,097341,378281,278266,143405,238151,197212,73854,89363,946213,394165,19261,52148,20074,16619,3480-31,72127,367
       Short-term Investments 
4,354
63,442
0
0
1,851
0
2,310
1,617
2,142
0
0
0
1,123
373
2,805
700
1,696
0
1,303
2,113
1,174
1,595
1,694
2,168
1,821
3,306
3,360
0
0
0
3,446
0
0
0
0003,4460003,3603,3061,8212,1681,6941,5951,1742,1131,30301,6967002,8053731,1230002,1421,6172,31001,8510063,4424,354
       Net Receivables 
407,351
0
0
340,071
351,367
349,180
626,491
641,029
565,322
640,212
634,666
518,109
635,893
722,682
583,134
743,346
674,214
530,600
718,266
627,954
662,583
610,100
726,606
659,997
741,791
545,760
722,965
690,947
645,660
668,955
769,871
748,055
808,564
800,294
800,294808,564748,055769,871668,955645,660690,947722,965545,760741,791659,997726,606610,100662,583627,954718,266530,600674,214743,346583,134722,682635,893518,109634,666640,212565,322641,029626,491349,180351,367340,07100407,351
       Inventory 
266,161
0
0
277,745
284,038
327,886
512,479
490,768
457,219
448,294
414,627
401,827
381,067
437,959
443,956
475,760
490,649
497,008
523,385
520,245
489,389
512,241
533,028
543,858
530,735
529,042
550,558
576,474
581,384
570,653
575,624
596,359
612,454
601,433
601,433612,454596,359575,624570,653581,384576,474550,558529,042530,735543,858533,028512,241489,389520,245523,385497,008490,649475,760443,956437,959381,067401,827414,627448,294457,219490,768512,479327,886284,038277,74500266,161
       Other Current Assets 
10,179
0
0
56,349
62,362
50,174
147,403
134,312
98,143
115,516
81,661
73,157
73,556
207,821
187,641
79,378
80,517
79,956
109,769
119,483
120,346
128,651
239,745
159,902
113,316
87,849
38,982
101,725
57,077
93,916
96,216
94,874
56,236
49,536
49,53656,23694,87496,21693,91657,077101,72538,98287,849113,316159,902239,745128,651120,346119,483109,76979,95680,51779,378187,641207,82173,55673,15781,661115,51698,143134,312147,40350,17462,36256,3490010,179
   > Long-term Assets 
481,774
0
0
529,083
569,956
564,451
3,196,694
3,150,747
3,066,092
3,116,618
3,076,292
2,498,112
2,455,680
2,617,100
2,575,882
2,493,817
2,454,494
2,400,409
2,459,578
2,404,072
2,419,556
2,499,290
2,487,804
2,454,207
2,387,523
2,319,280
2,279,097
2,231,004
2,094,706
2,076,353
2,024,442
1,947,684
1,913,639
1,854,799
1,854,7991,913,6391,947,6842,024,4422,076,3532,094,7062,231,0042,279,0972,319,2802,387,5232,454,2072,487,8042,499,2902,419,5562,404,0722,459,5782,400,4092,454,4942,493,8172,575,8822,617,1002,455,6802,498,1123,076,2923,116,6183,066,0923,150,7473,196,694564,451569,956529,08300481,774
       Property Plant Equipment 
407,404
0
0
457,617
486,758
489,947
569,328
567,498
544,146
658,457
647,605
624,033
609,153
611,453
606,072
600,895
595,169
595,136
597,946
459,651
639,003
622,636
602,770
587,436
589,360
578,377
571,275
560,799
550,137
544,785
528,937
532,897
523,693
522,748
522,748523,693532,897528,937544,785550,137560,799571,275578,377589,360587,436602,770622,636639,003459,651597,946595,136595,169600,895606,072611,453609,153624,033647,605658,457544,146567,498569,328489,947486,758457,61700407,404
       Goodwill 
28,441
0
0
26,005
26,444
26,338
386,475
410,616
426,226
421,640
420,017
419,671
419,504
514,733
527,475
522,690
522,814
522,758
549,091
566,406
593,017
602,893
600,974
599,504
598,853
599,156
599,206
598,631
598,629
598,549
598,533
598,324
597,436
597,497
597,497597,436598,324598,533598,549598,629598,631599,206599,156598,853599,504600,974602,893593,017566,406549,091522,758522,814522,690527,475514,733419,504419,671420,017421,640426,226410,616386,47526,33826,44426,0050028,441
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
16,373
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000016,373000000000000
       Intangible Assets 
45,929
0
0
45,461
44,599
48,166
1,788,533
1,733,020
1,654,969
1,591,158
1,553,330
1,435,801
1,382,753
1,475,161
1,423,826
1,349,113
1,304,626
1,262,954
1,293,325
1,232,727
1,166,922
1,209,818
1,204,224
1,159,005
1,096,093
1,055,319
1,015,376
982,531
890,423
859,272
819,944
780,189
732,377
689,136
689,136732,377780,189819,944859,272890,423982,5311,015,3761,055,3191,096,0931,159,0051,204,2241,209,8181,166,9221,232,7271,293,3251,262,9541,304,6261,349,1131,423,8261,475,1611,382,7531,435,8011,553,3301,591,1581,654,9691,733,0201,788,53348,16644,59945,4610045,929
       Other Assets 
10,929
0
0
17,015
12,155
746,137
452,358
439,613
440,751
445,363
455,340
15,607
16,455
15,753
18,509
21,119
149,300
19,561
19,216
145,288
473,696
21,792
79,836
108,262
17,631
0
13,612
0
0
0
0
0
0
0
000000013,612017,631108,26279,83621,792473,696145,28819,21619,561149,30021,11918,50915,75316,45515,607455,340445,363440,751439,613452,358746,13712,15517,0150010,929
> Total Liabilities 
1,394,762
0
0
1,665,821
1,717,471
1,727,607
3,605,102
3,666,729
3,456,373
3,584,805
3,512,787
3,308,219
3,319,102
3,987,342
3,685,740
3,689,340
3,661,101
3,593,362
3,632,781
3,591,243
3,572,691
3,481,561
3,850,529
3,851,664
3,590,413
3,464,410
3,518,012
3,495,699
3,452,558
3,473,004
3,513,989
3,494,658
3,610,957
3,424,638
3,424,6383,610,9573,494,6583,513,9893,473,0043,452,5583,495,6993,518,0123,464,4103,590,4133,851,6643,850,5293,481,5613,572,6913,591,2433,632,7813,593,3623,661,1013,689,3403,685,7403,987,3423,319,1023,308,2193,512,7873,584,8053,456,3733,666,7293,605,1021,727,6071,717,4711,665,821001,394,762
   > Total Current Liabilities 
225,073
0
0
259,237
296,883
313,051
669,736
749,271
553,850
599,530
546,159
534,910
550,406
965,065
655,019
667,886
676,902
636,779
672,862
667,335
677,243
602,043
993,064
817,995
752,800
703,709
777,350
760,601
846,595
834,388
1,114,353
1,095,209
1,129,771
1,075,824
1,075,8241,129,7711,095,2091,114,353834,388846,595760,601777,350703,709752,800817,995993,064602,043677,243667,335672,862636,779676,902667,886655,019965,065550,406534,910546,159599,530553,850749,271669,736313,051296,883259,23700225,073
       Short-term Debt 
1,197,472
1,197,472
0
64,562
89,482
89,171
99,478
199,820
21,715
37,852
38,051
38,288
36,954
346,945
47,075
46,198
57,474
42,357
43,705
45,449
46,037
46,349
131,130
106,572
104,639
145,262
166,477
122,512
227,624
228,665
451,646
381,021
340,255
337,544
337,544340,255381,021451,646228,665227,624122,512166,477145,262104,639106,572131,13046,34946,03745,44943,70542,35757,47446,19847,075346,94536,95438,28838,05137,85221,715199,82099,47889,17189,48264,56201,197,4721,197,472
       Short Long Term Debt 
1,197,472
1,197,472
0
0
89,482
14,415
21,678
121,694
21,449
21,445
21,445
21,468
21,479
330,736
30,756
30,776
45,228
29,817
30,461
33,689
30,614
30,523
114,920
89,940
89,961
129,965
150,405
106,533
213,125
212,660
435,519
364,692
324,213
321,790
321,790324,213364,692435,519212,660213,125106,533150,405129,96589,96189,940114,92030,52330,61433,68930,46129,81745,22830,77630,756330,73621,47921,46821,44521,44521,449121,69421,67814,41589,482001,197,4721,197,472
       Accounts payable 
60,033
0
0
66,639
70,013
84,221
169,046
124,539
114,846
546,389
502,686
495,857
103,021
594,361
602,428
618,070
154,140
581,422
597,927
591,212
132,867
541,801
563,834
533,440
166,843
136,922
139,527
177,400
145,530
176,975
201,778
235,000
258,691
192,532
192,532258,691235,000201,778176,975145,530177,400139,527136,922166,843533,440563,834541,801132,867591,212597,927581,422154,140618,070602,428594,361103,021495,857502,686546,389114,846124,539169,04684,22170,01366,6390060,033
       Other Current Liabilities 
63,820
0
0
128,036
137,388
228,830
401,212
424,912
416,130
15,289
5,422
765
401,702
23,759
5,516
3,618
459,750
13,000
31,230
30,674
495,816
13,893
298,100
177,983
480,959
421,525
471,346
460,689
473,441
313,122
460,929
479,188
546,867
545,748
545,748546,867479,188460,929313,122473,441460,689471,346421,525480,959177,983298,10013,893495,81630,67431,23013,000459,7503,6185,51623,759401,7027655,42215,289416,130424,912401,212228,830137,388128,0360063,820
   > Long-term Liabilities 
1,159,566
0
0
1,398,198
1,420,588
1,392,187
2,935,366
2,917,458
2,902,523
2,985,275
2,966,628
2,773,309
2,768,696
3,022,277
3,030,721
3,021,454
2,984,199
2,956,583
2,959,919
2,923,908
2,895,448
2,879,518
2,857,465
3,033,669
2,837,613
2,760,701
2,740,662
2,735,098
2,605,963
2,638,616
2,399,636
2,399,449
2,481,186
2,348,814
2,348,8142,481,1862,399,4492,399,6362,638,6162,605,9632,735,0982,740,6622,760,7012,837,6133,033,6692,857,4652,879,5182,895,4482,923,9082,959,9192,956,5832,984,1993,021,4543,030,7213,022,2772,768,6962,773,3092,966,6282,985,2752,902,5232,917,4582,935,3661,392,1871,420,5881,398,198001,159,566
       Long term Debt Total 
0
0
0
0
0
0
2,680,525
2,675,108
2,669,681
2,687,408
2,681,778
2,678,131
2,674,509
2,871,963
2,764,578
2,757,139
2,735,264
2,728,212
2,720,117
2,687,668
2,680,053
2,672,661
2,622,447
2,607,217
2,591,981
2,561,724
2,589,737
0
0
0
0
0
0
0
00000002,589,7372,561,7242,591,9812,607,2172,622,4472,672,6612,680,0532,687,6682,720,1172,728,2122,735,2642,757,1392,764,5782,871,9632,674,5092,678,1312,681,7782,687,4082,669,6812,675,1082,680,525000000
       Long term Debt 
1,159,566
0
0
0
1,395,261
1,392,187
2,641,305
2,675,108
2,630,598
2,625,152
2,619,788
2,614,412
2,609,046
2,807,310
2,800,239
2,757,139
2,735,264
2,728,212
2,757,341
2,687,668
2,680,053
2,672,661
2,661,303
2,607,217
2,591,981
2,601,852
2,589,737
2,582,815
2,427,451
2,419,600
2,177,578
2,169,607
2,161,790
2,153,979
2,153,9792,161,7902,169,6072,177,5782,419,6002,427,4512,582,8152,589,7372,601,8522,591,9812,607,2172,661,3032,672,6612,680,0532,687,6682,757,3412,728,2122,735,2642,757,1392,800,2392,807,3102,609,0462,614,4122,619,7882,625,1522,630,5982,675,1082,641,3051,392,1871,395,2610001,159,566
       Capital Lease Obligations 
0
0
0
0
0
0
39,220
0
39,083
145,308
141,294
137,185
135,542
141,351
143,332
137,353
123,876
125,154
129,741
11,760
127,351
124,583
122,505
120,962
123,487
121,442
118,592
115,340
109,947
113,569
112,042
110,362
107,136
103,732
103,732107,136110,362112,042113,569109,947115,340118,592121,442123,487120,962122,505124,583127,35111,760129,741125,154123,876137,353143,332141,351135,542137,185141,294145,30839,083039,220000000
       Warrants
0
0
0
0
0
0
11,900
0
0
0
0
0
0
12,563
12,380
11,932
11,804
13,079
14,112
15,260
16,907
16,420
17,885
22,375
24,949
27,527
32,106
0
0
0
0
0
0
0
000000032,10627,52724,94922,37517,88516,42016,90715,26014,11213,07911,80411,93212,38012,56300000011,900000000
       Other Liabilities 
9,202
0
0
0
25,327
22,369
242,983
242,350
232,842
231,222
222,152
38,532
39,583
30,977
35,031
36,746
87,267
32,719
71,969
220,980
48,522
43,237
89,867
88,554
97,117
0
48,405
0
0
0
0
0
0
0
000000048,405097,11788,55489,86743,23748,522220,98071,96932,71987,26736,74635,03130,97739,58338,532222,152231,222232,842242,350242,98322,36925,3270009,202
       Long-term Liabilities Other 
0
0
0
0
0
0
240,467
240,589
231,664
231,222
222,152
38,532
39,583
7,892
10,721
252,383
237,131
215,292
63,255
220,980
198,488
190,437
79,213
232,163
245,632
41,456
39,282
41,388
8,215
91,481
90,496
90,999
94,051
80,086
80,08694,05190,99990,49691,4818,21541,38839,28241,456245,632232,16379,213190,437198,488220,98063,255215,292237,131252,38310,7217,89239,58338,532222,152231,222231,664240,589240,467000000
       Deferred Long Term Liability 
0
0
0
0
0
0
2,491
1,761
1,178
0
0
0
3,099
3,434
3,174
2,908
2,648
0
0
0
1,603
1,345
2,453
2,356
2,206
0
1,926
0
0
0
0
0
0
0
00000001,92602,2062,3562,4531,3451,6030002,6482,9083,1743,4343,0990001,1781,7612,491000000
> Total Stockholder Equity
-185,290
-185,290
0
-436,606
-385,739
0
494,501
501,105
896,363
472,205
459,656
395,724
346,788
318,376
305,995
301,040
344,932
323,015
346,107
383,166
366,973
391,125
280,327
297,469
183,979
134,668
318,169
330,860
19,781
-63,724
-57,465
-93,432
-109,267
1,016,435
1,016,435-109,267-93,432-57,465-63,72419,781330,860318,169134,668183,979297,469280,327391,125366,973383,166346,107323,015344,932301,040305,995318,376346,788395,724459,656472,205896,363501,105494,5010-385,739-436,6060-185,290-185,290
   Common Stock
2,675
0
0
2,716
2,716
0
2,985
2,986
2,987
2,989
2,991
2,991
2,992
2,994
2,996
2,997
2,997
3,007
3,012
3,014
3,014
3,028
3,032
3,035
3,036
3,054
3,062
3,064
3,066
3,086
3,095
3,098
3,099
0
03,0993,0983,0953,0863,0663,0643,0623,0543,0363,0353,0323,0283,0143,0143,0123,0072,9972,9972,9962,9942,9922,9912,9912,9892,9872,9862,98502,7162,716002,675
   Retained Earnings -594,867-607,062-575,981-575,825-581,819-490,176-391,527-401,209-413,126-406,183-401,850-399,161-278,353-276,197-269,820-265,583-280,115-286,821-283,784-274,809-262,813-377,880-345,752-80,746-63,844-20,920-12,152-19,104-357,980-382,785-424,35400-175,168
   Capital Surplus 
0
0
0
0
0
0
517,122
520,160
530,438
537,159
544,161
565,641
606,966
611,600
617,504
623,133
628,413
634,484
642,657
650,539
658,350
666,799
675,588
683,745
691,629
700,722
708,233
0
0
0
0
0
0
0
0000000708,233700,722691,629683,745675,588666,799658,350650,539642,657634,484628,413623,133617,504611,600606,966565,641544,161537,159530,438520,160517,122000000
   Treasury Stock0000000000000000000000000000000000
   Other Stockholders Equity 
-12,797
9,345
0
-14,968
11,278
357,980
517,122
520,160
530,438
537,159
544,161
565,641
606,966
611,600
617,504
623,133
586,752
634,484
642,657
650,539
658,350
666,799
675,588
683,745
691,629
700,722
708,233
715,450
539,240
538,720
545,701
553,233
560,206
1,562,241
1,562,241560,206553,233545,701538,720539,240715,450708,233700,722691,629683,745675,588666,799658,350650,539642,657634,484586,752623,133617,504611,600606,966565,641544,161537,159530,438520,160517,122357,98011,278-14,96809,345-12,797



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,793,957
Cost of Revenue-1,773,519
Gross Profit1,020,4381,020,438
 
Operating Income (+$)
Gross Profit1,020,438
Operating Expense-667,150
Operating Income249,326353,288
 
Operating Expense (+$)
Research Development196,559
Selling General Administrative476,436
Selling And Marketing Expenses0
Operating Expense667,150672,995
 
Net Interest Income (+$)
Interest Income0
Interest Expense-258,595
Other Finance Cost-0
Net Interest Income-258,595
 
Pretax Income (+$)
Operating Income249,326
Net Interest Income-258,595
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-55,013553,665
EBIT - interestExpense = -55,013
-98,023
141,709
Interest Expense258,595
Earnings Before Interest and Taxes (EBIT)203,582203,582
Earnings Before Interest and Taxes (EBITDA)439,773
 
After tax Income (+$)
Income Before Tax-55,013
Tax Provision-18,863
Net Income From Continuing Ops-73,876-73,876
Net Income-116,886
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,544,631
Total Other Income/Expenses Net-304,339258,595
 

Technical Analysis of Amneal
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Amneal. The general trend of Amneal is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Amneal's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Amneal Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Amneal Pharmaceuticals, Inc. Class A Common Stock.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 8.32 < 9.045 < 9.1.

The bearish price targets are: 7.69 > 7.07 > 7.02.

Know someone who trades $AMRX? Share this with them.👇

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current macd is 0.19010861.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Amneal price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Amneal. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Amneal price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Moving Average Convergence/Divergence (MACD) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current adx is 29.17.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Amneal shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current sar is 8.00380931.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current rsi is 65.61. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Relative Strength Index (RSI) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Amneal price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Stochastic Oscillator ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current cci is 135.79.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Commodity Channel Index (CCI) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current cmo is 41.37.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Chande Momentum Oscillator (CMO) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current willr is -6.84931507.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Williams %R ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Amneal Pharmaceuticals, Inc. Class A Common Stock.

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current atr is 0.24520111.

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Average True Range (ATR) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current obv is -2,823,344.

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily On-Balance Volume (OBV) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Amneal Pharmaceuticals, Inc. Class A Common Stock. The current mfi is 40.73.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Money Flow Index (MFI) ChartAmneal Pharmaceuticals, Inc. Class A Common Stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Amneal Pharmaceuticals, Inc. Class A Common Stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Amneal Pharmaceuticals, Inc. Class A Common Stock Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Amneal Pharmaceuticals, Inc. Class A Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.611
Ma 20Greater thanMa 507.885
Ma 50Greater thanMa 1007.616
Ma 100Greater thanMa 2007.874
OpenGreater thanClose8.210
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Amneal with someone you think should read this too:
  • Are you bullish or bearish on Amneal? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Amneal? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Amneal Pharmaceuticals, Inc. Class A Common Stock

I send you an email if I find something interesting about Amneal Pharmaceuticals, Inc. Class A Common Stock.


Comments

How you think about this?

Leave a comment

Stay informed about Amneal Pharmaceuticals, Inc. Class A Common Stock.

Receive notifications about Amneal Pharmaceuticals, Inc. Class A Common Stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.